Lunai Bioworks subsidiary BioSymetrics and Brigham and Women鈥檚 Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics
Lunai Bioworks (NASDAQ:RENB) subsidiary BioSymetrics and Brigham and Women's Hospital have been awarded a $1.85M NIH STTR grant to develop an AI-powered drug discovery platform for Alcohol Use Disorder (AUD). The fast-tracked Phase I and II grant from NIAAA will support the development of a platform combining artificial intelligence with in vivo zebrafish screening.
The collaboration, co-led by Dr. Calum MacRae from Brigham and Women's Hospital, aims to address the therapeutic needs of over 19 million Americans affected by AUD. The project will integrate BioSymetrics' machine learning tools with experimental phenotyping capabilities to create a scalable discovery engine and identify novel small molecules for potential AUD therapies.
Lunai Bioworks (NASDAQ:RENB), tramite la sua controllata BioSymetrics, e il Brigham and Women's Hospital hanno ottenuto un finanziamento NIH STTR da 1,85 milioni di dollari per sviluppare una piattaforma di scoperta di farmaci basata sull'intelligenza artificiale per il Disturbo da Uso di Alcol (AUD). Il grant, accelerato e che copre le Fasi I e II ed 猫 erogato dall'NIAAA, sosterr脿 lo sviluppo di una piattaforma che combina AI con screening in vivo su zebrafish.
La collaborazione, co-diretta dal Dr. Calum MacRae del Brigham and Women's Hospital, si propone di rispondere ai bisogni terapeutici di oltre 19 milioni di americani affetti da AUD. Il progetto unir脿 gli strumenti di machine learning di BioSymetrics alle capacit脿 di fenotipizzazione sperimentale per creare un motore di scoperta scalabile e identificare nuove piccole molecole con potenziale terapeutico per l'AUD.
Lunai Bioworks (NASDAQ:RENB), a trav茅s de su filial BioSymetrics, y el Brigham and Women's Hospital han recibido una subvenci贸n NIH STTR de 1,85 millones de d贸lares para desarrollar una plataforma de descubrimiento de f谩rmacos impulsada por IA para el Trastorno por Consumo de Alcohol (AUD). La subvenci贸n, acelerada y que cubre las Fases I y II otorgada por la NIAAA, apoyar谩 el desarrollo de una plataforma que combina inteligencia artificial con cribado in vivo en zebrafish.
La colaboraci贸n, codirigida por el Dr. Calum MacRae del Brigham and Women's Hospital, busca atender las necesidades terap茅uticas de m谩s de 19 millones de estadounidenses afectados por AUD. El proyecto integrar谩 las herramientas de aprendizaje autom谩tico de BioSymetrics con capacidades experimentales de fenotipado para crear un motor de descubrimiento escalable e identificar nuevas peque帽as mol茅culas con potencial terap茅utico para el AUD.
Lunai Bioworks (NASDAQ:RENB)鞚� 鞛愴殞靷� BioSymetrics鞕� 敫岆Μ瓴� 鞐劚 氤戩洂(Brigham and Women's Hospital)鞚� 鞎岇綌鞓� 靷毄 鞛レ暊(AUD) 旃橂鞝� 臧滊皽鞚� 鞙勴暅 AI 旮半皹 鞁犾暯 氚滉铂 頂岆灚韽� 臧滊皽鞚� 鞙勴暣 1.85氚彪 雼煬 攴滊鞚� NIH STTR 氤挫“旮�鞚� 靾橃棳氚涭晿鞀惦媹雼�. NIAAA臧� 牍犽ゴ瓴� 歆勴枆頃橂姅 1路2雼硠 氤挫“旮堨溂搿�, 鞚戈车歆�電リ臣 鞝滊笇霛柬敿鞁�(in vivo) 鞀ろ伂毽嫕鞚� 瓴绊暕頃� 頂岆灚韽� 臧滊皽鞚� 歆�鞗愴暕雼堧嫟.
敫岆Μ瓴� 鞐劚 氤戩洂鞚� 旃茧熂 毵ル爤鞚� 氚曥偓臧� 瓿惦彊 毂呾瀯鞚� 毵‰姅 鞚措矆 順戨牓鞚� AUD搿� 瓿犿喌氚涬姅 1,900毵� 氇呾澊 雱橂姅 氙戈淡鞚�鞚� 旃橂鞝� 鞖旉惮毳� 頃搓舶頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�. 氤� 頂勲鞝濏姼電� BioSymetrics鞚� 毹胳嫚霟嫕 霃勱惮鞕� 鞁ろ棙鞝� 響滍槃順� 攵勳劃 電ル牓鞚� 韱淀暕頃� 頇曥灔 臧�電ロ暅 氚滉铂 鞐旍鞚� 甑稌頃橁碃 AUD 旃橂 頉勲炒臧� 霅� 靸堧鞖� 鞝�攵勳瀽 頇旐暕氍检潉 氚滉荡頃� 鞓堨爼鞛呺媹雼�.
Lunai Bioworks (NASDAQ:RENB), via sa filiale BioSymetrics, et le Brigham and Women's Hospital ont obtenu une subvention NIH STTR de 1,85 million de dollars pour d茅velopper une plateforme de d茅couverte de m茅dicaments aliment茅e par l'IA pour le trouble li茅 脿 l'usage d'alcool (AUD). La subvention acc茅l茅r茅e de phases I et II, financ茅e par la NIAAA, soutiendra le d茅veloppement d'une plateforme combinant intelligence artificielle et criblage in vivo sur zebrafish.
La collaboration, codirig茅e par le Dr Calum MacRae du Brigham and Women's Hospital, vise 脿 r茅pondre aux besoins th茅rapeutiques de plus de 19 millions d'Am茅ricains atteints d'AUD. Le projet int茅grera les outils de machine learning de BioSymetrics aux capacit茅s de ph茅notypage exp茅rimental pour cr茅er un moteur de d茅couverte 茅volutif et identifier de nouvelles petites mol茅cules candidates pour des th茅rapies potentielles contre l'AUD.
Lunai Bioworks (NASDAQ:RENB)-Tochter BioSymetrics und das Brigham and Women's Hospital wurden mit einem NIH STTR-Zuschuss in H枚he von 1,85 Mio. USD ausgezeichnet, um eine KI-gest眉tzte Wirkstoffentdeckungsplattform f眉r Alkoholgebrauchsst枚rung (AUD) zu entwickeln. Der beschleunigte Phase-I/II-Zuschuss der NIAAA wird die Entwicklung einer Plattform unterst眉tzen, die K眉nstliche Intelligenz mit in vivo Zebrafisch-Screenings kombiniert.
Die Zusammenarbeit, die gemeinsam von Dr. Calum MacRae vom Brigham and Women's Hospital geleitet wird, zielt darauf ab, die therapeutischen Bed眉rfnisse von 眉ber 19 Millionen Amerikanern mit AUD zu adressieren. Das Projekt wird die Machine-Learning-Tools von BioSymetrics mit experimentellen Ph盲notypisierungsf盲higkeiten verbinden, um eine skalierbare Entdeckungsmaschine zu schaffen und neue kleine Molek眉le mit Potenzial als AUD-Therapien zu identifizieren.
- Secured significant NIH STTR grant worth $1.85M for AUD drug discovery platform
- Strategic collaboration with prestigious Brigham and Women's Hospital
- Addresses large market opportunity with over 19 million Americans affected by AUD
- Expands company's AI capabilities into addiction therapeutics space
- Grant funding contingent upon achieving Phase I milestones
- Early-stage research with no guaranteed therapeutic outcomes
Insights
Lunai's subsidiary secured $1.85M NIH grant for AI-driven AUD drug discovery, strengthening its position in the underserved addiction therapeutics market.
This NIH STTR grant represents a notable development for Lunai Bioworks, providing
The collaboration with Brigham and Women's Hospital and Dr. Calum MacRae adds substantial credibility to this venture. Dr. MacRae's expertise in zebrafish models has already yielded important insights in cardiovascular and neurological diseases, suggesting this approach has established scientific validity that's now being applied to addiction.
The focus on Alcohol Use Disorder represents entry into an underserved therapeutic area affecting over 19 million Americans. Current AUD treatments have limited efficacy, creating a substantial market opportunity if novel compounds can be identified. The zebrafish model offers advantages in screening speed and cost compared to traditional mammalian models, potentially accelerating the early discovery pipeline.
From a strategic perspective, this grant reinforces Lunai's positioning at the intersection of AI and in vivo biology for drug discovery. While the
BETHESDA, MD / / September 11, 2025 / Lunai Bioworks Inc.'s (NASDAQ:RENB) wholly-owned subsidiary BioSymetrics Inc. today announced the award of a prestigious Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH). The funding, awarded jointly to BioSymetrics and Brigham and Women's Hospital, will support the development of a novel platform that combines artificial intelligence and in vivo zebrafish screening to accelerate drug discovery for Alcohol Use Disorder (AUD), a disease affecting more than 19 million Americans and substantially contributing to the development of both oncologic and neurologic disorders.
The grant is a fast-tracked Phase I and Phase II application awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) with a total value of
The joint program, co-led by Dr. Calum MacRae, Vice Chair for Scientific Innovation at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School, will unite expertise in AI-driven behavioral phenotyping with large-scale drug screening models.
"Despite its prevalence, AUD remains critically underserved in terms of therapeutic innovation," said Dr. Gabe Musso, Chief Scientific Officer at BioSymetrics. "This STTR award allows us to build on our AI-based behavioral screening platform and extend its impact to a space where there is urgent unmet need. We're excited to work alongside Dr. MacRae and his team to translate complex phenotypic insights into actionable drug candidates."
The platform will integrate BioSymetrics' proprietary machine learning tools with experimental phenotyping capabilities developed in Dr. MacRae's lab. The project aims to deliver both a scalable discovery engine for AUD as well as novel small molecules that could form the basis for future therapies.
"This collaboration represents the convergence of two longstanding commitments: to advance precision therapeutics and to reimagine how we model and treat complex human diseases," said Dr. Calum MacRae. "Our work in zebrafish has already transformed understanding of cardiovascular and neurological diseases, this grant allows us to bring the same rigor and creativity to the treatment of addiction."
Lunai Bioworks's subsidiary, BioSymetrics is a biomedical AI company focused on creating scalable frameworks for data-driven therapeutic discovery pioneering AI-powered platforms for precision neurology and other high-burden diseases. BioSymetrics contributes core data science infrastructure to Lunai's broader mission.
"This is a natural extension of Lunai's approach where we are harnessing AI and in vivo biology to identify therapies faster, with greater precision, and in areas of profound clinical need," said David Weinstein, CEO of Lunai Bioworks.
The project also reflects a key strategic priority for Lunai: using AI to accelerate early-stage discovery while ensuring that translational tools remain tied to measurable, real-world phenotypes.
About Lunai Bioworks
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Media Contact:
David Weinstein
Chief Executive Officer
[email protected]
SOURCE: Lunai Bioworks Inc.
View the original press release on ACCESS Newswire
FAQ
What is the value of the NIH grant awarded to Lunai Bioworks (RENB) and Brigham and Women's Hospital?
What is the purpose of Lunai Bioworks' (RENB) new research collaboration?
Who is leading the RENB research collaboration with Brigham and Women's Hospital?
What technology will Lunai Bioworks (RENB) use in its AUD research platform?
How many Americans are affected by Alcohol Use Disorder according to RENB's announcement?
